Literature DB >> 14586293

Anthrax--an overview.

Serkan Oncü1, Selcen Oncü, Serhan Sakarya.   

Abstract

Anthrax, a disease of mammals (including humans), is caused by a spore-forming Gram-positive bacilli called Bacillus anthracis. Anthrax is one of the oldest threats to humanity, and remains endemic in animals in many parts of the world. The incidence of anthrax has decreased in developed countries, but it remains a considerable health problem in developing countries. The disease is transmitted to humans by contact with sick animals or their products, such as wool, skin, meat etc. Capsular polypeptide and anthrax toxin are the principal virulence factors of B. anthracis. Anthrax toxin consists of three proteins called protective antigen, edema factor, and lethal factor, each of which is nontoxic but acts synergistically. Human anthrax has three major clinical forms: cutaneous, inhalational, and gastrointestinal. The diagnosis is easily established in cutaneous cases, characterized by black eschar. Severe intoxication and collapse during the course of bronchopneumonia or hemorrhagic enteritis should prompt suspicion of anthrax. Treatment with antibiotics is mandatory. If untreated, anthrax in all forms can lead to septicemia and death. Recently, considerable attention has been focused on the potential for B. anthracis to be used in acts of biological terrorism. The ease of laboratory production and its dissemination via aerosol led to its adoption by terrorists, as shown by recent events in the USA. A good knowledge of anthrax, its epidemiology, pathogenesis, clinical forms and potential as a biological weapon is essential for timely prevention and treatment. This review summarizes the current knowledge on anthrax.

Entities:  

Mesh:

Year:  2003        PMID: 14586293

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  10 in total

1.  Reaerosolization of fluidized spores in ventilation systems.

Authors:  Paula Krauter; Arthur Biermann
Journal:  Appl Environ Microbiol       Date:  2007-02-09       Impact factor: 4.792

2.  Acquired coagulant factor VIII deficiency induced by Bacillus anthracis lethal toxin in mice.

Authors:  Der-Shan Sun; Po-Chien Lee; Jyh-Hwa Kau; Yung-Luen Shih; Hsin-Hsien Huang; Chen-Ru Li; Chin-Cheng Lee; Yu-Ping Wu; Kuo-Ching Chen; Hsin-Hou Chang
Journal:  Virulence       Date:  2015-04-23       Impact factor: 5.882

3.  Gastrointestinal anthrax: clinical experience in 5 cases.

Authors:  Ghodratollah Maddah; Abbas Abdollahi; Mehrdad Katebi
Journal:  Caspian J Intern Med       Date:  2013

4.  PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis.

Authors:  Pauline Yoong; Raymond Schuch; Daniel Nelson; Vincent A Fischetti
Journal:  J Bacteriol       Date:  2006-04       Impact factor: 3.490

Review 5.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

6.  Coping with multiple virulence factors: which is most important?

Authors:  Erin E McClelland; Paul Bernhardt; Arturo Casadevall
Journal:  PLoS Pathog       Date:  2005-12       Impact factor: 6.823

7.  Cutaneous anthrax outbreak associated with handling dead animals, Rhino Camp sub-county: Arua District, Uganda, January-May 2018.

Authors:  Vivian Ntono; Daniel Eurien; Lilian Bulage; Daniel Kadobera; Julie Harris; Alex Riolexus Ario
Journal:  One Health Outlook       Date:  2021-04-28

8.  Gamma-phage lysin PlyG sequence-based synthetic peptides coupled with Qdot-nanocrystals are useful for developing detection methods for Bacillus anthracis by using its surrogates, B. anthracis-Sterne and B. cereus-4342.

Authors:  Shilpakala Sainathrao; Ketha V Krishna Mohan; Chintamani Atreya
Journal:  BMC Biotechnol       Date:  2009-07-22       Impact factor: 2.563

Review 9.  Bacillus anthracis edema factor substrate specificity: evidence for new modes of action.

Authors:  Martin Göttle; Stefan Dove; Roland Seifert
Journal:  Toxins (Basel)       Date:  2012-07-06       Impact factor: 4.546

10.  Complement C3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response.

Authors:  Ravi V Kolla; Suresh Chintalapati; Mojgan Sabet; Eugenio Santelli; Robert C Liddington; Michael David; Joshua Fierer; Donald Guiney; Robert C Rickert
Journal:  PLoS One       Date:  2007-10-17       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.